IFI35通过CCL2分泌来限制三阴性乳腺癌的抗瘤免疫力
Baojin Xu1,2,3, Hefen Sun4,5, Simeng Liu1,2
1Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Oncogene
|January 12, 2024
概括
IFI35蛋白限制了三阴性乳腺癌 (TNBC) 的抗瘤免疫力. 降低IFI35可增强T细胞活性,使TNBC对免疫疗法敏感,这表明IFI35是一种新的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 三阴性乳腺癌 (TNBC) 是具有有限治疗选择的侵袭性.
- 免疫疗法提供了好处,但面临着广泛的治疗耐药性.
研究的目的:
- 研究IFI35在TNBC进展和免疫治疗反应中的作用.
- 确定TNBC的新型治疗点.
主要方法:
- 在瘤组织中量化IFI35表达.
- 利用乳腺癌细胞系和异种移植模型.
- 进行RNA测序和免疫细胞分析.
主要成果:
- IFI35在TNBC上升调节,并由INTERFERON-γ诱导.
- IFI35促进了骨髓系衍生抑制细胞的透和CD8+T细胞的枯竭.
- IFI35的消去增强了CD8+T细胞的透和抗瘤免疫力.
- IFI35促进CCL2分泌,重塑瘤的免疫微环境.
结论:
- 在TNBC中,IFI35抑制了抗瘤免疫力.
- 准IFI35可以使TNBC对免疫疗法,特别是抗PD-1疗法敏感.
- IFI35代表了TNBC的一个潜在的新免疫治疗点.
相关概念视频
01:27Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K